QCG
ARCT icon

Quadrant Capital Group’s Arcturus Therapeutics ARCT Stock Holding History

Quadrant Capital Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-52
Closed -$882 – 2717
2022
Q4 		$882 Sell
52
-92
-64% -$1.6K ﹤0.01% 2563
2022
Q3 		$2K Buy
+144
New +$2.42K ﹤0.01% 2330
2022
Q2 		– Sell
-21
Closed -$1K – 2522
2022
Q1 		$1K Buy
+21
New +$536 ﹤0.01% 2240
2021
Q4 		– Sell
-79
Closed -$4K – 2498
2021
Q3 		$4K Buy
+79
New +$3.54K ﹤0.01% 1917

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quadrant Capital Group's ARCT Position: Q1 2023 in Review

Quadrant Capital Group sold out of Arcturus Therapeutics (ARCT) in Q1 2023, closing a stake of 52 shares — an estimated $882 sold.

Quadrant Capital Group first reported a position in ARCT in Q3 2021 and held it in 4 quarters. The position peaked at $4K in Q3 2021. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2023.

  • Quadrant Capital Group reported no remaining Arcturus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 52 Arcturus Therapeutics shares in Q1 2023, an estimated $882.
  • Quadrant Capital Group first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 4 quarters.
  • Quadrant Capital Group's Arcturus Therapeutics position peaked at $4K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.